Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Year
  • 1
    In: Annals of Oncology, 2017, Vol. 28(suppl9)
    ISSN: 0923-7534
    E-ISSN: 1569-8041
    Source: Oxford University Press
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: JAMA, 09 February 2011, Vol.305(6), pp.564-5; author reply 566
    Keywords: Antibodies, Monoclonal -- Therapeutic Use ; Colorectal Neoplasms -- Drug Therapy ; Ras Proteins -- Genetics
    ISSN: 00987484
    E-ISSN: 1538-3598
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Annals of Oncology, 2016, Vol. 27(suppl7)
    Keywords: Medicine;
    ISSN: 0923-7534
    E-ISSN: 1569-8041
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Annals of Oncology, 2018, Vol. 29(suppl7)
    Keywords: Medicine;
    ISSN: 0923-7534
    E-ISSN: 1569-8041
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Expert Review of Gastroenterology & Hepatology, 01 February 2015, Vol.9(2), pp.133-139
    Description: In recent years, various molecular target agents have been investigated for gastric cancer. VEGF is one of the most potent angiogenic factors and is a signaling molecule secreted by many solid tumors. High VEGF expression is one of the characteristic features of gastric carcinomas, thus targeting VEGF is considered a promising strategy for gastric cancer. Ramucirumab, an anti-VEGF receptor antibody, has proven to be effective for previously treated advanced gastric cancer. Details of ramucirumab, including two pivotal Phase III studies, will be discussed in this review. Ramucirumab, with or without chemotherapy, improved survival in gastric cancer after previous systemic chemotherapy, thus becoming the standard of care for this patient population. Optimal timing of ramucirumab use and adequate biomarkers for patient selection as well as mechanism of resistance should be explored in future research.
    Keywords: Anti-Vegfr Monoclonal Antibodies ; Gastric Cancer ; Ramucirumab ; Vascular Endothelial Growth Factor Receptor ; Medicine
    ISSN: 1747-4124
    ISSN: 14363291
    E-ISSN: 1747-4132
    E-ISSN: 14363305
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Language: English
    In: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association / International Gastric Cancer Association, Japanese Gastric Cancer Association [編], 2017, Vol.20, Passage No.Suppl.1, pp.S102-110
    Description: Material Type: 記事・論文
    Keywords: Chemotherapy ; Gastric Cancer ; Human Epidermal Growth Factor Receptor 2 ; Immune Checkpoint Inhibitors ; Vascular Endothelial Growth Factor Receptor 2
    ISSN: 14363291
    Source: Zassaku –(Japanese Periodicals Index) (National Diet Library of Japan)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Gastric Cancer, 2012, Vol.15(2), pp.137-143
    Description: Byline: Kohei Shitara (1), Junko Ikeda (1), Chihiro Kondo (1), Daisuke Takahari (1), Takashi Ura (1), Kei Muro (1), Keitaro Matsuo (2) Keywords: Chemotherapy; Gastric cancer; Prognostic factor; Randomized trial; Stratification Abstract: Background There is no consensus on which patient characteristics are the most suitable to report or to be used as stratification factors in clinical trials for advanced gastric cancer (AGC), to our knowledge. Methods We conducted a comprehensive review of published randomized trials for AGC to examine the patient characteristics that were reported. Results Among the 67 analyzed trials, age, gender, performance status, proportion of patients with measurable disease, and previous gastrectomy were frequently reported (〉69%). Histology, number of disease sites, and adjuvant treatment were reported in less than 50% of trials. Although the reporting of second-line chemotherapy has increased in recent trials, it remains at less than 50%. Notably, recent trials have tended to include patients with better performance status and less locally advanced disease, with Asian trials more frequently including patients with more diffuse histology and less locally advanced disease or liver metastasis than non-Asian trials. Stratification was conducted in approximately 60% of the trials, using quite variable stratifying factors. Conclusion Inconsistency exists in the reporting of patient characteristics, the characteristics themselves, and the use of stratification factors in clinical trials for AGC. A consensus set of important patient characteristics and strata may be necessary to conduct and interpret quality randomized studies. Author Affiliation: (1) Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan (2) Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan Article History: Registration Date: 25/07/2011 Received Date: 14/05/2011 Accepted Date: 24/07/2011 Online Date: 13/08/2011 Article note: Electronic supplementary material The online version of this article (doi: 10.1007/s10120-011-0083-8) contains supplementary material, which is available to authorized users.
    Keywords: Chemotherapy ; Gastric cancer ; Prognostic factor ; Randomized trial ; Stratification
    ISSN: 1436-3291
    E-ISSN: 1436-3305
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Journal of Physical Chemistry & Biophysics, 2012, Vol.02(02)
    ISSN: Journal of Physical Chemistry & Biophysics
    E-ISSN: 21610398
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: Translational gastroenterology and hepatology, 2017, Vol.2, pp.26
    ISSN: 2415-1289
    Source: MEDLINE/PubMed (U.S. National Library of Medicine)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: International Journal of Clinical Oncology, 2013, Vol.18(3), pp.539-546
    Description: Byline: Kohei Shitara (1), Akira Sawaki (2,3), Keitaro Matsuo (4), Chihiro Kondo (1), Daisuke Takahari (1), Takashi Ura (1), Masahiro Tajika (2), Yasumasa Niwa (2), Kei Muro (1) Keywords: Capecitabine; Chemotherapy; Cisplatin; Gastric cancer; S-1 Abstract: Background Based on the results of the SPIRITS trial, combination chemotherapy of S-1 plus cisplatin (SP) is now considered the standard treatment for patients with advanced gastric cancer (AGC) in Japan. On the other hand, several non-Japanese studies have shown the efficacy of capecitabine plus cisplatin (XP), which has been used as the reference arm in recent global studies of AGC. Methods We retrospectively compared the efficacy and safety of SP and XP in first-line treatment for patients with AGC. Results From August 2006 to November 2008, 26 AGC patients received XP in the context of 2 global trials (AVAGAST and ToGA), and 50 patients received SP during the same period. The objective response rate was 43.2 % in the SP group and 50 % in the XP group, with no significant difference (p = 0.62). There were also no significant differences in progression-free survival (median 5.8 vs. 5.2 months p = 0.91) and overall survival (median 13.8 vs. 13.5 months p = 0.97) between the SP and XP groups. The frequencies of hematological toxicities of grade 3 or more and non-hematological toxicities were not significantly different between the 2 groups. Although grade 1 or 2 hand--foot syndrome was more common in the XP group, no patients experienced grade 3 or more. Conclusions Although the retrospective nature of this study and the small number of patients is a major limitation, SP and XP were associated with similar efficacy and safety in patients with AGC. Author Affiliation: (1) Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan (2) Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan (3) Nagoya Daini Red Cross Hospital, Nagoya, Japan (4) Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan Article History: Registration Date: 18/04/2012 Received Date: 06/03/2012 Accepted Date: 16/04/2012 Online Date: 03/05/2012
    Keywords: Capecitabine ; Chemotherapy ; Cisplatin ; Gastric cancer ; S-1
    ISSN: 1341-9625
    E-ISSN: 1437-7772
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages